Antiinfectives targeting enzymes and the proton motive force

Xinxin Feng, Wei Zhu, Lici A. Schurig-Briccio, Steffen Lindert, Carolyn Shoen, Reese Hitchings, Jikun Li, Yang Wang, Noman Baig, Tianhui Zhou, Boo Kyung Kim, Dean C. Crick, Michael Cynamond, J. Andrew McCammon, Robert B. Gennis, and Eric Oldfield

There is a growing need for new antibiotics. Compounds that target the proton motive force (PMF), uncouplers, represent one possible class of compounds that might be developed because they are already used to treat parasitic infections, and there is interest in their use for the treatment of other diseases, such as diabetes. Here, we tested a series of compounds, most with known antiinfective activity, for uncoupler activity. Many cationic amphiphiles tested positive, and some targeted isopenoiid biosynthesis or affected lipid bilayer structure. As an example, we found that clomiphene, a recently discovered undecaprenyl diphosphate synthase inhibitor active against Staphylococcus aureus, is an uncoupler. Using in silico screening, we then found that the anti-glioblastoma multi-forme drug lead vacquinol is an inhibitor of Mycobacterium tuberculosis tuberculosinyl adenosine synthase, as well as being an uncoupler. Because vacquinol is also an inhibitor of M. tuberculosis cell growth, we used similarity searches based on the vacquinol structure, finding analogs with potent (∼0.5–2 μg/mL) activity against M. tuberculosis and S. aureus. Our results give a logical explanation of the observation that most new tuberculosis drug leads discovered by phenotypic screens and genome sequencing are highly lipophilic (logP >5.7) bases with membrane targets because such species are expected to partition into hydrophobic membranes, inhibiting membrane proteins, in addition to collapsing the PMF. This multiple targeting is expected to be of importance in overcoming the development of drug resistance because targeting membrane physical properties is expected to be less susceptible to the development of resistance.

molecular dynamics simulations | clofazimine | bedaquiline | clomiphene | vacquinol

There is a need for new antibiotics, due to the increase in drug resistance (1, 2). For example, some studies report that by 2050, absent major improvements in drug discovery and use, more individuals will die from drug-resistant bacterial infections than from cancer, resulting in a cumulative effect on global gross domestic product of as much as $100 trillion dollars (3, 4). To discover new drugs, new targets, leads, concepts, and implementations are needed (5, 6).

Currently, one major cause of death from bacterial infections is tuberculosis (TB) (7), where very highly drug-resistant strains have been found (8). Therapy is lengthy, even with drug-sensitive strains, and requires combination therapies with four drugs. Two recent TB drugs/drug leads (9–11) are TMC207 [bedaquiline (1); Sirturo] and SQ109 (2) (Fig. 1). Bedaquiline (1) targets the Mycobacterium tuberculosis ATP synthase (9) whereas SQ109 (2) has been proposed to target MmpL3 (mycobacterial membrane protein large 3), a trehalose monomycolate transporter essential for cell wall biosynthesis (12). SQ109 (2) is a lipophilic base containing an adamantyl “headgroup” connected via an ethylene diamine “linker” to a geranyl (C15) “side chain,” and in recent work (13), we synthesized a series of 11 analogs of SQ109 (2) finding that the ethanalamine (3) was more potent than was SQ109 (2) against M. tuberculosis H37Rv [0.063 vs. 0.25 μg/mL minimal inhibitory concentration (MIC)], and that at least one protonatable nitrogen in the linker was essential for activity. The latter observation suggested to us that SQ109 (2) and ethanalamine (3) might have activity as uncouplers, collapsing the proton motive force (PMF; ∆P) used to drive ATP synthesis, because we had observed similar uncoupling effects for lipophilic bases, US Food and Drug Administration (FDA)-approved drugs, in trypanosomatid parasites (14, 15). The PMF is given by ΔP = −Δψ − ZΔφH, where Δψ is the electrical or membrane potential component of ΔP, ΔφH is the transmembrane pH gradient, and Z is 2.303RT/F where R is the gas constant, T is temperature (in kelvins), and F is the Faraday constant.

We found with SQ109 and its analogs that the most potent M. tuberculosis cell growth inhibitors investigated did indeed collapse pH gradients and Δψ, as also observed with the lipophilic bases amiodarone (4) (14) and dronedarone (5) (15), antiarhythmia drugs, in trypanosomatid parasites (14, 15), and SQ109 (2) also acts as an uncoupler in Trypanosoma cruzi (19). Amiodarone (4) and dronedarone (5) had little uncoupling activity against host cells. In related work, Li et al. (20) found that other TB drug leads, BM212 (6), THPP-2 (7), Ro 48-8071 (8), the urea A1235 (9), and the indolecarboxamide 2418 (10), most of which had been proposed to target MmpL3, likewise had activity as uncouplers, collapsing pH gradients, and in some cases were active against the
nonreplicative bacteria found under hypoxic conditions. Several of these compounds also have enzyme targets. For example, SQ109 (2), ethanolamine (3), and Ro 48-8071 (8) have been found (13, 20) to inhibit enzymes involved in menaquinone biosynthesis, particularly the prenyl transferase 1,4-dihydroxy-2-naphthoate octaprenyltransferase (MenA) and human oxidosqualene cyclase (OSC) (21), and bedaquiline (1) is a potent ATP synthase inhibitor, indicating the possibility of multitarget activity for such compounds. These results are of interest because they show that several recently discovered M. tuberculosis drug leads can act as uncouplers in addition to targeting one or more enzymes that are essential for bacterial cell growth, with membrane targeting being of particular interest because it might be expected to be less susceptible to the development of resistance than is purely enzyme targeting, and SQ109 (2) does indeed have a low frequency of resistance in M. tuberculosis ($\approx 2.55 \times 10^{-11}$) (22). Targeting membrane lipids is also a reason for the low frequency of resistance found with, for example, amphotericin [which binds to ergosterol in fungi and protozoa (23)], as well as the recently discovered teixobactin, which binds to lipid II/III (24).

In other work by Goldman (25), it has been pointed out that most of the new TB drug leads that have been discovered by phenotypic screens and genome sequencing are highly lipophilic (logP $\sim 5.7$) bases with membrane targets, which suggested to us the possibility that these drug leads might function by targeting the PMF, as well as membrane proteins. Although targeting the PMF might be expected to be purely mitotoxic, Stock et al. (26) have shown that compounds with logP $> 6$ have generally low mitotoxicity, which is due, they proposed, to low membrane permeability attributable to accumulation in lipophilic membranes.

Perhaps the most well-known uncoupler is 2,4-dinitrophenol (DNP; 11). DNP functions as a protonophore, a proton-translocating molecule, and analogs such as niclosamide (12) and nitazoxanide (13) [active form, tizoxanide (14)] are used clinically: niclosamide (12) to treat tapeworm infections (27) and nitazoxanide (13) to treat infections due to Giardia lamblia (28) and Cryptosporidium parvum. Nitazoxanide (13) has also been in clinical trials for the treatment of Helicobacter pylori and Clostridium difficile infections. Interestingly, SQ109 (2) has similar activity against both organisms (29), and with H. pylori, SQ109 (2) once again has a very low ($\approx 10^{-12}$) frequency of resistance (29). In addition, nitazoxanide (13) has been found to kill both replicating and nonreplicating M. tuberculosis (30–33), and Nathan and coworkers (30, 31) were unable to develop resistant colonies using up to $10^{12}$ cfu, proposing a dual “PMF + unknown target” mechanism of action. Niclosamide (12) has been proposed
as a lead for the treatment of type II diabetes (34), and it is also an inhibitor of breast cancer stem-like cells (35) and an inhibitor of Pseudomonas aeruginosa quorum sensing (36). There has also been very recent interest in the development of DNP analogs such as DNP methyl ether (37), for treating diabetes, and of controlled-release DNP formulations (38) as mild hepatic mitochondrial uncouplers for treating hypertriglyceridermia, insulin resistance, hepatic steatosis, and diabetes. Niclosamide (12) and tizoxanide (14) are both FDA-approved, and closanol (15) is an anthelmintic uncoupler in veterinary use, and all could provide leads for new and improved inhibitors that target other pathogens. There has also been considerable renewed interest (39) in the use of pyrazinoic acid (16), which functions, at least in part, as a protonophore uncoupler, for treating TB (39, 40), stimulating our interest in discovering new TB drug leads with uncoupler activity.

In this work, we carried out three main types of investigation. First, we investigated the uncoupling effects of 21 compounds (primarily known drugs or drug leads) on uncoupling (Δψ/ΔpH collapse) in bacterial inverted membrane vesicles (IMVs) and in porcine mitochondria. Second, we investigated drug–membrane interactions using differential scanning calorimetry (DSC) and electron paramagnetic resonance (EPR) spectroscopy. Third, we used molecular dynamics (MD) structure-based in-silico screening and structure-similarity searches to find prenyl synthase inhibitors with uncoupler activity, leading finally to a consideration of the future prospects for discovering new “enzyme + uncoupler” antifungal drug leads.

Results and Discussion

Targeting the PMF. We first investigated two TB drugs that seemed likely to act, at least in part, as protonophore uncouplers: clofazimine (17) (Fig. 1) and TMC207 (1), which have similar logP and pKa values to each other as well as to amiodarone (4, Table 1), a known uncoupler we worked on previously. Clofazimine (17) was originally developed as a TB drug (41) but later was used extensively (42) in treating leprosy, caused by another Mycobacterium, Mycobacterium leprae. There have been several mechanisms of action demonstrated or proposed for clofazimine (17), including a redox cycling reaction involving the generation of reactive oxygen species (43), and clofazimine is currently of interest for use in combination therapies with benzothiazinones (44). We used the sealed, inside-out IMV assay used previously to investigate SQ109 (2) (13) with 9-amino-6-chloro-2-methoxyacridine (ACMA) as a pH-sensitive fluorescence probe of the pH gradient, ΔpH (computed as illustrated in Fig. S1). Using ATP hydrolysis through the ATP synthase, protons are driven inside the membrane vesicles, protonated ACMA accumulates, and its fluorescence is self-quenched. The same effect is seen with addition of succinate/O2, where, again, H+ is pumped into the vesicles. Addition of clofazimine (17) caused rapid increases in ACMA fluorescence in both succinate-oxidation and ATP-powered assays, as shown in Fig. 2A and B. These results are very similar to the results we reported previously for SQ109 (2) (13), as well as to the results we found for TMC207 (1) in the same assays (Fig. 2 C and D). TMC207 (1) is thought to target the ATP synthase in M. tuberculosis, but in recent work, it has also been proposed to act as an uncoupler, targeting again the ATP synthase (45). However, there is expected to be a significant protonophore contribution to its activity because clofazimine (17) (not thought to target the ATP synthase) and TMC207 (1) have almost identical logP, pKa, and logD, and computed charge values (at pH 7.4) (Table 1), even though the chemical structures are completely different. For clofazimine (17), the values are logP = 7.3, pKa = 9.29, logD = 5.23, and charge = 0.99; for TMC207 (1), the values are logP = 7.13, pKa = 8.91, logD = 5.42, and charge = 0.98 (Table 1). It thus seems likely that clofazimine (17), as well as TMC207 (1), can act, at least in part, in a similar manner to the potent anionic protonophores, such as carbonyl cyanide m-chlorophenyl hydrzone.

Table 1. Uncoupling effects, computed molecular properties, and M. tuberculosis cell growth inhibition for compounds investigated

<table>
<thead>
<tr>
<th>No.</th>
<th>Compound</th>
<th>ΔψMV,%</th>
<th>ΔψEC50 (mto), μM</th>
<th>pKa</th>
<th>LogP</th>
<th>LogD</th>
<th>Charge</th>
<th>Mtb, μM</th>
<th>Enzyme target</th>
<th>FDA-approved</th>
</tr>
</thead>
<tbody>
<tr>
<td>4</td>
<td>Amiodarone</td>
<td>0.17</td>
<td>0.44</td>
<td>16</td>
<td>50</td>
<td>8.5</td>
<td>7.6</td>
<td>6.4</td>
<td>0.95</td>
<td>6.2</td>
</tr>
<tr>
<td>17</td>
<td>Clofazimine</td>
<td>0.14</td>
<td>0.27</td>
<td>30</td>
<td>&gt;100</td>
<td>9.3</td>
<td>7.3</td>
<td>5.2</td>
<td>0.99</td>
<td>0.53</td>
</tr>
<tr>
<td>36</td>
<td>Clophene</td>
<td>1.2</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>9.3</td>
<td>7.3</td>
<td>4.6</td>
<td>0.99</td>
<td>NA</td>
</tr>
<tr>
<td>1</td>
<td>TMC207</td>
<td>0.46</td>
<td>0.9</td>
<td>2.1</td>
<td>&gt;100</td>
<td>8.9</td>
<td>7.1</td>
<td>5.4</td>
<td>0.98</td>
<td>0.11</td>
</tr>
<tr>
<td>3</td>
<td>TMC207</td>
<td>2.2</td>
<td>1.0</td>
<td>6.2</td>
<td>45</td>
<td>8.5</td>
<td>6.5</td>
<td>5.1</td>
<td>0.99</td>
<td>0.41</td>
</tr>
<tr>
<td>20</td>
<td>Tamofoxene</td>
<td>0.45</td>
<td>1.1</td>
<td>20</td>
<td>8.8</td>
<td>6.4</td>
<td>4.8</td>
<td>0.97</td>
<td>19</td>
<td>1</td>
</tr>
<tr>
<td>22</td>
<td>Rafoxifene</td>
<td>0.42</td>
<td>1.5</td>
<td>0</td>
<td>49</td>
<td>8.5</td>
<td>5.7</td>
<td>5.2</td>
<td>0.82</td>
<td>27</td>
</tr>
<tr>
<td>21</td>
<td>OH-tamoxifen</td>
<td>1.5</td>
<td>2.6</td>
<td>8.2</td>
<td>14</td>
<td>8.7</td>
<td>5.7</td>
<td>4.5</td>
<td>0.96</td>
<td>12</td>
</tr>
<tr>
<td>24</td>
<td>BPH1276</td>
<td>0.30</td>
<td>3.8</td>
<td>3.5</td>
<td>&gt;100</td>
<td>3.4</td>
<td>5.5</td>
<td>2.2</td>
<td>0.99</td>
<td>NA</td>
</tr>
<tr>
<td>5</td>
<td>Dronedaron</td>
<td>1.7</td>
<td>0.51</td>
<td>0</td>
<td>11</td>
<td>9.8</td>
<td>5.3</td>
<td>4</td>
<td>0.98</td>
<td>NA</td>
</tr>
<tr>
<td>33</td>
<td>SQ109</td>
<td>0.094</td>
<td>0.66</td>
<td>35</td>
<td>84</td>
<td>6.7</td>
<td>4.6</td>
<td>1.7</td>
<td>1.22</td>
<td>0.30</td>
</tr>
<tr>
<td>37</td>
<td>NCS13316</td>
<td>12</td>
<td>11</td>
<td>14</td>
<td>60</td>
<td>9.5</td>
<td>4.6</td>
<td>2.5</td>
<td>0.99</td>
<td>4.5</td>
</tr>
<tr>
<td>35</td>
<td>D3</td>
<td>92</td>
<td>31</td>
<td>0</td>
<td>&gt;100</td>
<td>11</td>
<td>4.2</td>
<td>4.2</td>
<td>0</td>
<td>NA</td>
</tr>
<tr>
<td>25</td>
<td>BPH1330</td>
<td>0.17</td>
<td>0.2</td>
<td>&gt;100</td>
<td>9.6</td>
<td>4.1</td>
<td>0.6</td>
<td>0.1</td>
<td>&lt;1</td>
<td>310</td>
</tr>
<tr>
<td>32</td>
<td>BAM15</td>
<td>1.3</td>
<td>0.4</td>
<td>17</td>
<td>1</td>
<td>12</td>
<td>3.9</td>
<td>3.9</td>
<td>0</td>
<td>NA</td>
</tr>
<tr>
<td>26</td>
<td>BPH889</td>
<td>110</td>
<td>&gt;100</td>
<td>2</td>
<td>&gt;100</td>
<td>5.6</td>
<td>3.9</td>
<td>2.3</td>
<td>0.98</td>
<td>NA</td>
</tr>
<tr>
<td>24</td>
<td>D2</td>
<td>40</td>
<td>51</td>
<td>2.9</td>
<td>&gt;100</td>
<td>11</td>
<td>3.9</td>
<td>3.8</td>
<td>0.03</td>
<td>NA</td>
</tr>
<tr>
<td>9</td>
<td>AU1235</td>
<td>3.9</td>
<td>1.3</td>
<td>10</td>
<td>52</td>
<td>11</td>
<td>3.7</td>
<td>3.7</td>
<td>0</td>
<td>0.031</td>
</tr>
<tr>
<td>27</td>
<td>Platensimycin</td>
<td>12</td>
<td>&gt;100</td>
<td>2.9</td>
<td>&gt;100</td>
<td>9.2</td>
<td>3.2</td>
<td>0</td>
<td>&lt;0.10</td>
<td>27</td>
</tr>
<tr>
<td>39</td>
<td>Trimethoprim</td>
<td>77</td>
<td>&gt;100</td>
<td>0.7</td>
<td>&gt;100</td>
<td>7.2</td>
<td>1.3</td>
<td>1</td>
<td>0.47</td>
<td>1,800</td>
</tr>
<tr>
<td>18</td>
<td>Sulfamethoxazole</td>
<td>110</td>
<td>&gt;100</td>
<td>0.7</td>
<td>&gt;100</td>
<td>6.2</td>
<td>0.8</td>
<td>0.1</td>
<td>&lt;0.92</td>
<td>34</td>
</tr>
</tbody>
</table>

Compounds with a green background have logP > 6 or logP < 3; compounds with a yellow background have logP between 3 and 6. BAM15, N,N,N'-N'-bis(2-fluorophenyl)-[1,2,5]oxadiazolo[3,4-b]pyrazine-5,6-diamine; DHRF, dihydrofolate reductase; DHPS, dihydropteroate synthetase; ER, estrogen receptors; FAS, fatty acid synthase; ion, ion channel; Mtb, M. tuberculosis; NA, not applicable (no results reported); NDH-2, NADH:quinone oxidoreductase II; OSC, oxidosqualene cyclase.

*ΔpH EC50 is calculated as shown in Fig. S1 using different compound concentrations.

**Δψ** collapse of EdIMV measured at 1 μM compound.

*Drugs that are currently approved for use in humans by the United States Food and Drug Administration.*
some of which have activity against \( \Delta \psi \) and a large surface area, leading to a low charge density. Charge delocalization is likely to contribute to membrane solubility. What is also of interest with clofazimine (\(\text{pK}_a\) refer to small in EcIMV and MsIMV, respectively), molecular properties (logD, \(\text{pK}_a\), charge), and cell growth inhibition \(M.\) \(\text{tuberculosis}\) (Mtts). (E) Heat map of correlation coefficients between uncoupling activities \(\Delta \psi\) in EcIMV and Mtts, \(\Delta \psi\) in EcIMV, \(\Delta \psi\) in mitochondria (mito), molecular properties (logD, \(\text{pK}_a\), charge), and cell growth inhibition (Mtts) for Mtts inhibitors shown in Table 1. High activities refer to small \(\Delta \psi\)/Mtts \(E_{\text{C50}}\) values, and high \(\Delta \psi\) collapse/logD charge. Molecular property calculations were carried out using Marvin ChemAxon (https://www.chemaxon.com/marvin/sketch/index.php) and Chemicalize (www.chemicalize.org). All structures are shown in Fig. 1. AMIO, amiodarone; CFZ, clofazimine; PLAT, platensimycin; RAL, raloxifene; SMX, sulfamethoxazole; TAM, tamoxifen; TMP, trimethoprim.

In recent work, we (49) and others (50, 51) identified several anionic, bacterial cell growth inhibitors that, in addition to inhibiting bacteria-specific enzyme targets, might have activity as uncouplers, as expected for lipophilic weak acid, classic uncouplers like CCCP and DNP. We first investigated seven compounds with known antibacterial activity and a diverse range of proposed protein targets. In all cases, we anticipated a negative net charge (at pH 7.4). The compounds were the benzoic acid BPH1463 (23) (Fig. 1), which inhibits undecaprenyl diphosphate synthase (UPPS) (52); the benzoic acid BPH1127 (24) developed by Pharmacia, which has been proposed to target transcription/translation (50) but also inhibits UPPS (49); the diketoacid BPH1130 (25) that inhibits \(S.\) \(\text{aureus UPPS}\), \(S.\) \(\text{aureus dehydrogenase}\) (CrtM) (52), and \(S.\) \(\text{aureus cell growth}\), as well as inducing formation of neutrophil extracellular traps (52); the dihydropridin-2-one-3-carboxamide BPH1889 (26) developed by Novartis, which inhibits \(S.\) \(\text{pneumoniae UPPS}\), \(S.\) \(\text{pneumoniae, and S. aureus cell growth}\) (51); platensimycin (27); and sulfamethoxazole (28). The phenol platensimycin (27) is an antibiotic that inhibits fatty acid biosynthesis (53), as well as having antiangiogenic activity (54). There is also renewed interest in sulfamethoxazole (28)/trimethoprim (29) combined activity against \(M.\) \(\text{tuberculosis}\) (55), and sulfamethoxazole has a sulfonamide that can act as a weak acid. However, of these compounds, only the benzoate (23) had significant activity as a protonophore (Table 1), due perhaps to relatively unfavorable interactions of most species with anionic membrane lipids.

In addition to cationic and anionic uncouplers, there are several known neutral uncouplers. In early work, it was found that in the industrial preparation of the herbicide Diuron [3-(3,4-dichlorophenyl)-1,1-dimethylurea], there was an impurity that had potent activity as an uncoupler: \(N,N\)-bis(3,4-dichlorophenyl)urea (30) (56). In later work (57), it was found that...
$N,N$-bis[(para-trifluoromethyl)phenyl]urea (31) was an even more potent uncoupler (in plant mitochondria and thylakoid membranes), and this compound displayed no titration behavior between pH 2 and pH 9 (57), as expected for a urea. More recently, the analog 1-(2-acetoxyethyl)-3-(2,3,4-trifluorophenyl)urea [AU1235 (9)] has been found to kill replicating but not nonreplicating $M$. tuberculosis (58) and to collapse the pH gradient in $M$. smegmatis (20). The detailed molecular mechanism of action of the neutral uncouplers is not known but has been proposed to be related to either conformational changes in membrane proteins or changes in phospholipid bilayer organization (57). We find that AU1235 (9) collapses the pH gradient in the EcIMV assay, consistent with the NMR observations (20). In addition, we find that $N,N'$-bis(2-fluoro-phenyl)-1,2,5-oxadiazole-3,4-b-pyrazine-5,6-diamine (BAM15; 32), a mitochondrial uncoupler that does not depolarize the plasma membrane (59), also acts as a (neutral) uncoupler in the EcIMV assay. Clearly, further work is needed to clarify the molecular mechanism of action of the neutral uncouplers, and we briefly investigate below the possible effects of AU1235 on membrane bilayer structure. Finally, we investigated several other compounds that have been reported to act as uncouplers in $S$. aureus (60): pyrazinocarbazole (33), D2 (34), and D3 (35). Only the pyrazinocarbazole (33) showed uncoupler activity and although it has previously been reported (60) to collapse $\Delta \psi$ selectively in $S$. aureus, it appears to act here as a protonophore, consistent with its computed $pK_a$ (62) and $\log \gamma$ (47) values.

**Mechanisms of Action of Coupling.** We next tested all compounds for their effects on the membrane potential, $\Delta \psi$, in EcIMVs, using oxonol VI as the fluorescence probe and on $\Delta \psi$ in porcine mitochondria using 3,3-dipropylthiacyanocarboanide iodide [DSC5(5)] fluorescence as the probe (61) (Table 1). Most compounds tested were active in $\Delta \psi$ collapse in EcIMVs, but very few were active in porcine mitochondria (Table 1).

When examining the results on $\Delta \psi$ vs. collapse in IMVs, it can be seen from the heat map shown in Fig. 2E that $\Delta \psi$ collapse (of $\Delta \psi$ EcIMV and $\Delta \psi$ MsIMV) and EcIMV $\Delta \psi$ collapse are highly correlated (red, Pearson $R$ values are shown on the heat map), which suggests that these compounds mainly affect the proton gradient across the membrane and are not highly bacteria-specific. The $R$ value for EcIMV $\Delta \psi$ and $\Delta \psi$ collapse is $\sim 0.8$, comparable to the $\sim 0.89$ reported previously (13) for a highly homologous series of compounds, all SQ109 analogs. However, the $\Delta \psi$ EcIMV collapse in bacterial IMVs ($\Delta \psi$ EcIMV, $\Delta \psi$ MsIMV, and $\Delta \psi$) is not highly correlated with $\Delta \psi$ collapse in mitochondrial $M$. tuberculosis (mito). Reasons are unknown but could be due, in part, to differences in lipid composition, lipid-protein interactions, and possibly the role of transporters. The $\Delta \psi$ EcIMV collapse in the bacterial IMVs has a linear correlation with logD and charge, but not with $pK_a$ [because a parabolic $pK_a$ dependence is expected (62)]. These results indicate that logD (computed from logP, $pK_a$, and pH) and charge are both important descriptors for uncoupling activity. More importantly, the $\Delta \psi$ EcIMV collapse with bacterial IMVs is correlated with the IC$_{50}$ for $M$. tuberculosis cell growth inhibition (Mtb), as would be expected if uncoupling activity contributes to the inhibitory potency of many of these compounds. The $R$ values are not high ($R = 0.6-0.7$) because, of course, in many if not most instances, enzyme targeting will dominate. Nevertheless, as shown in Fig. 2F, the compounds with good $M$. tuberculosis activity are the ones with the most potent activities in $\Delta \psi$ EcIMV collapse of bacterial IMVs, high logD, and positive charge (as indicated by the black square in Fig. 2F): clofazimine, TMC207, and SQ109. So, in general, the lipophilic, catonic species are the best uncouplers, as well as the best $M$. tuberculosis cell growth inhibitors. The mycobacterial cell wall is, of course, an exceptionally strong barrier for drug penetration (63), and, in addition, mycobacteria produce many active efflux pumps. However, although a highly hydrophobic cell wall is a strong barrier for most drugs, for highly hydrophobic species [e.g., SQ109, clofazimine, TMC307] targeting inner membrane proteins, it could actually act as a drug “reservoir,” enabling effective enzyme targeting. In addition, efflux pumps that are powered by the PMF will be inhibited by such species.

The results discussed above suggested that it might be of interest to investigate drug-membrane interactions with neutral (zwiterionic) and anionic model lipid bilayer membranes. We show in Fig. 3 $A-E$ the DSC results for drugs binding to the saturated, zwiterionic lipid, 1,2-dipalmitoyl-sn-glycero-3-phosphocholine [DPPC], having a gel-to-liquid crystal phase transition temperature ($T_m$) $\sim 42^\circ C$, and in Fig. 3 $F$ the results for the anionic lipid, 1,2-dimyristoyl-sn-glycero-3-phosphatidic acid (DMPA; $T_m$ $\sim 46^\circ C$ at pH 7). We chose to investigate three types of inhibitors: the cationic species SQ109 (2), amiodarone (4), and TMC207 (1), all of which are expected to have relatively localized charges; the cationic species clofazimine (17), where the charge is expected to be delocalized over the $\pi$-system; and the neutral species, AU1235 (9).

With the cationic species [SQ109 (2), amiodarone (4), and TMC207 (1)], there are $\sim 0.9-\sim 4^\circ C$ decreases in $T_m$ [the maximum in the heat capacity at constant pressure ($C_p$)-vs.-$T$ thermogram] with DPPC, with amiodarone (4) also broadening the thermal transition, which means that with amiodarone, there are both fluid and ordered lipid domains present in the range of the broad transition (Fig. 3 $A-C$). However, there is essentially no change in $T_m$ ($\Delta T_m \sim 0.8^\circ C$) with clofazimine (17), only a slight broadening of the transition (Fig. 3D). With the neutral uncoupler, AU1235 (9), there is likewise only a small change in the transition, with $\Delta T_m = \sim 1.2^\circ C$ (Fig. 3E). Thus, the largest effects on the gel-to-liquid crystal phase transition with the protonating drugs molecules, the effects on the phase transition (Fig. S2 $A-E$) are, in most cases, quite similar to the effects seen with DPPC (which is zwiterionic), suggesting that the effects that are seen with both lipids are due, primarily, to a direct perturbation of chain packing. The exception is found with SQ109 (2), which causes a more extensive broadening and shifting of the phase transition with DMPA (Fig. S2 $F$) than found when it interacts with DPPC, due to enhanced chain packing with the singly protonated form, although more work is needed to pin-down the details of such drug-membrane interactions. With pure DMPA, the main transition is pH-dependent, and at pH 5 and pH 9, where the DMPA is deprotonated but SQ109 (2) remains (positively) charged, there are large shifts in $T_m$ (Fig. S2F).
In both the DPPC and DMPA systems, however, there are decreases in the thermal transition temperatures in the presence of SQ109 (2), which may be expected to increase membrane lipid disorder/fluidity and, arguably, uncoupler activity.

We also investigated the effects of four drug molecules, SQ109 (2), amiodarone (4), clofazimine (17), and AU1235 (9), on lipid order/dynamics, using the EPR spin label approach we used previously to investigate the effects of cholesterol on lipid membranes (64). Fig. 3 H and I show variable temperature results for DPPC and DMPA. With DPPC at 25 °C, all spectra correspond to an immobilized spin label, characteristic of a gel-like phase (64). As temperatures increase, DPPC + SQ109 has an EPR-detected phase transition between 30 °C and 35 °C, whereas pure DPPC and DPPC + clofazimine/AU1235 show phase transitions between 35 °C and 40 °C, as indicated by the red boxes in Fig. 3H. With DPPC + amiodarone (4), there is evidence for more than a single spectral component, consistent with the considerable broadening of the transition seen in DSC. Similar results are seen with DMPA with the four compounds, as shown in Fig. 3I. The DSC and EPR spin label results therefore both indicate that the largest effects on membrane structure are seen with the localized charge uncouplers, whereas the delocalized charge and neutral species have much smaller effects on bilayer structure.

Overall then, the results described here and in the previous sections indicate that many TB drugs and drug leads are quite potent uncouplers. In some cases, as discussed in the next section, these compounds also act as enzyme inhibitors, providing the possibility of multisite targeting. This possibility is, of course, of importance because most antibiotics that have been relatively resistant to the development of drug resistance over time have more than one target. We next consider one class of enzymes that might...
be particularly good targets for inhibitors that are also uncouplers: the isoprenoid or prenyl biosynthesis enzymes.

**Targeting Prenyl Synthases.** As a class, prenyl synthases are important drug targets. In addition, several protonophore uncouplers are known to act as prenyl synthase inhibitors. A plausible reason for this uncoupler/inhibitor relation is that most prenyl synthases use either cationic (transition state/reactive intermediate) or anionic (substrate/product) headgroups and they have substrates/products with large hydrophobic side chains. Therefore, cationic or anionic uncouplers with charged-hydrophobic structural characteristics can be well accommodated by the polar-nonpolar active site pockets of prenyl synthases, and may have high activity as competitive inhibitors. By way of some examples, we show in Fig. 4 the structures of six prenyl synthase drug targets, together with known enzyme inhibitors that are also uncouplers [several of which are FDA-approved drugs (4, 36) or are in clinical trials (2)]. All six proteins have polar-nonpolar active-site pockets that correlate with the involvement of charged-hydrophobic substrates/products or transition state/reactive intermediates, as shown in Fig. 4.

Fig. 4 A is a Phyre2 (65) model prediction for MenA [based on UbiA (66); Protein Data Bank (PDB) ID code 4OD5]. SQ109 analog 3 inhibits *M. smegmatis* ManE with an IC$_{50}$ of 4 μM and *E. coli* MenA with an IC$_{50}$ of 400 nM (13). Fig. 4B shows the structure of *S. aureus* dehydroquinate synthase, CrtM (PDB ID code 4EA1) and its inhibitor SQ109 (67), and Fig. 4C shows the structure of human OSC [a model for the trypanosomatid OSC drug targets; PDB ID code 1W6J (21)]. MenA and CrtM both have typical all-α-helical structures found in trans-prenyl synthases, whereas OSC has the two-domain structure found in the class II terpene cyclases. The proteins shown in Fig. 4 D-F all contain the cis-isoprenoid biosynthesis enzyme fold: UPPS [PDB ID code 2E98 (68)] in Fig. 4D; decaprenyl diphosphate synthase [DPPS; PDB ID code 2VG3 (69)] in Fig. 4E; and Rv3378c, tuberculosteryl adenine (TbAd) synthase [PDB ID code 3WQM (70)], in Fig. 4F. Rv3378c is of interest because it is a target for antivirulence-based therapeutics for TB. As one example of a UPPS uncoupler-inhibitor, we reported in recent work that the fertility drug clomiphene also had activity against *S. aureus* and that a major target was UPPS (71). What is interesting about the clomiphene (36) structure is that it is remarkably similar to the structure of tamoxifen (20), which itself has antifertility activity. We find an EC$_{50}$ of 1.2 μM for clomiphene (in the EcIMV assay; Table 1) in comparison to 0.39 μM for tamoxifen. Clomiphene also has an 8 μg/mL MIC against *Enterococcus faecium* (72) and a 0.22 μM IC$_{50}$ against liver stage malaria parasites (73), suggesting that there may be dual target activity in several pathogens. So, uncoupler-inhibitors are known for MenA, CrtM, OSC, DPPS, and UPPS, whereas uncoupler-inhibitors for Rv3378c have yet to be discovered.

Rv3378c catalyzes the formation of TbAd (74) (Fig. 5A) and related compounds (75). Transposon mutants of Rv3378c show inhibited phagosomal acidification, and Rv3378c is necessary for production of TbAd and related metabolites. Therefore, it is likely that one of the TbAd compounds controls intravacuolar pH (76). Here, we initially sought to discover inhibitors of Rv3378c that were also uncouplers, reasoning that the combination of direct uncoupling (as with SQ109) and antivirulence activity would be a good approach to killing intracellular *M. tuberculosis*. We thus carried out an in silico screen of a library of 1,013 compounds [from National Cancer Institute (NCI) diversity set III] using the MD-based structures reported previously (77). The X-ray structure of Rv3378c with a bound inhibitor is shown in Fig. 5B, together with one snapshot from an MD trajectory.

We tested 39 compounds (Fig. S3) from the in silico screen for Rv3378c inhibition activity using tuberculosis diphosphatase and 3H-adenosine as substrates. The structures of the compounds tested against S. aureus dehydroquinate synthase, CrtM (PDB ID code 4OD5) and its inhibitor SQ109 (78) are shown in red in Fig. S3. The most active compound was the ethanolamine NSC13316 (37), which had an IC$_{50}$ of 2.7 μM in Rv3378c inhibition (Fig. S4). Surprisingly, NSC13316 (37) has already been reported (79) to potently inhibit the growth of *M. tuberculosis*, with an MIC of 1.6 μg/mL (4.5 μM). This effect is not expected for a virulence-targeting drug lead. Moreover, NSC13316 (37), now known as vacquinol-1, has activity against glioblastoma multiforme (GBM) cancer cells (80), both in vitro and in vivo, and is thought to kill these tumor cells by an unusual mechanism involving a decrease in ATP levels and extensive vacuolization (81). NSC13316 (37) is, therefore, a potentially interesting new antifibrictive multitarget drug lead.

**Vacquinol Analogs as Antiinfective Drug Leads.** The observation that vacquinol is active against *M. tuberculosis* growth, as well as the antivirulence target Rv3378c, was of interest, so we next carried out a structure similarity search based on NSC13316 (37) and obtained 13 analogs from the NCI/Developmental Therapeutics Program Open Chemical Repository (dtp.cancer.gov/). We then tested NSC13316 (37) and these analogs (Fig. S5) for uncoupling activity in the EcIMV and MsIMV assays, finding that vacquinol (37) had an ~12–13 μM IC$_{50}$ (Fig. S4). Results for the analogs are summarized in Table S1.
The vacquinol class of compounds, 2-piperidinyl-4-quinoline-methanols, were originally developed as antimalarials (81, 82), and in addition to their activity against *M. tuberculosis* and brain cancer cells, they can inhibit efflux pumps and are of interest in combating multidrug resistance in cancer cells (79, 83, 84), suggesting the possibility that their uncoupling effects could contribute to a diverse range of activities. The fact that vacquinol also has promising in vivo activity against GBM, a good in vivo pharmacokinetic profile, oral bioavailability, and favorable overall preclinical characteristics (80), in addition to killing *M. tuberculosis*, makes it an interesting lead for antiinfective development.

We therefore next tested the 13 vacquinol analogs for growth inhibition activity against *M. tuberculosis* H37Rv and *M. tuberculosis* Erdman, as well as against another bacterium, *S. aureus*, and against the yeast *Saccharomyces cerevisiae*, basically to see if there were general growth inhibitory effects against bacteria and a fungus. We found that vacquinol and its analogs were quite potent in cell growth inhibition against each of these microorganisms, with the best IC50s for *M. tuberculosis* H37Rv, *M. tuberculosis* Erdman, *S. aureus*, and *S. cerevisiae* being 0.53, 1.5, 1.4, and 3.4 μg/mL, respectively (Table S1). Moreover, we found that the uncoupling activity of these compounds (EcIMV assay) correlated well with their bacterial and yeast cell growth inhibition potency, as well as with the growth inhibition of GBM cancer cells (Fig. 5C), with coefficients of cross-correlation larger than 0.7, suggesting the possibility that uncoupling is a contributor to the antibacterial/antifungal/anticancer activity of the vacquinol series.
Future Prospects for Enzyme/Uncoupler Drug Leads. The results we have presented above show that numerous FDA-approved drugs and other drug leads have activity as uncouplers. Pure uncouplers (without enzyme targets) are generally not expected to be good drug leads, although, as noted in the Introduction, some antiparasitics function in this way, plus there is considerable interest in the development of DNP prodrugs/formulations for treating diabetes, insulin resistance, and hepatic steatosis. Because we find that TB drugs like clofazimine, bedaquiline, and SQ109 all have protonophore uncoupler activity, it seems likely that one route to finding new leads will be to investigate analogs of the types of compounds we have discussed here, for antifungal, enzyme inhibition, and uncoupler activity.

It is also possible that prodrug uncouplers can be produced in some cases in much the same way that DNP-methyl ether is being developed to treat diabetes, or the nitazoxanide (14) is a prodrug for tizoxanide (14). As an example, with *M. tuberculosis*, it has recently been shown that the heatburn proton pump inhibitor drug lansoprazole is metabolized to lansoprazole sulfide (structures in Fig. 6), which has potent activity against *M. tuberculosis* inside macrophages (85), and similar antibacterial effects are seen with olanzapine (which is reduced to the active sulfide) in *Helicobacter pylori* (86), as well as with rabeprazole (87, 88). Lansoprazole, omeprazole, and rabeprazole are all proton pump inhibitors that contain benzimidazole groups with sulfioxide substituents. They can be reduced to sulfides, and this reduction correlates with a predicted large increase in benzimidazole pKₐ values (from ∼1 for the highly electron-withdrawing sulfide to ∼4.2 for the electron-donating sulfides), and this increased basicity would increase uncoupling activity (as would increase in logP of ∼1 unit). We tested lansoprazole, lansoprazole sulfide, and rabeprazole sulfide for uncoupling activity in the EcMV assay. Results are shown in Fig. 6. Our results indicate sulfide itself has no (∼1 mM) activity as an uncoupler, but the two sulfides have measurable activity, ∼70 μM for lansoprazole sulfide. The large changes in pKₐ predicted for benzimidazoles with sulfide/sulfone substituents, as well as the observation of uncoupling activity for the sulfides, are consistent with earlier work on sulfide/sulfone proton pump inhibitors (89), where uncoupling was observed with the sulfides, and suggests possible routes to new (pro)drug leads with multienzyme (enzyme and uncoupler) activity. This prodrug activity involving the host is also a contributor to the activity of a standard TB drug, pyrazinamide, which is now thought to act, in large part, as pyrazinamide, a modest uncoupler that has multiple targets (39, 90). A pictorial summary of a selection of such enzyme/uncoupler multitarget inhibitors is shown in Fig. 6.

Conclusions

We tested a series of cationic, neutral, and anionic compounds for uncoupler activity in *M. smegmatis* and *E. coli* IMV assays and in porcine liver mitochondria. The most active compounds in the IMV assays were cationic amphiphatic drugs. These drugs also inhibited *M. smegmatis* and *M. tuberculosis* cell growth. Clofazimine (17) and TMC207 (1) were particularly active uncouplers, comparable to CCCC. We investigated drug–membrane interactions using DSC and EPR, finding that lipophilic cations with localized charges had large effects on the lipid phase transition, whereas delocalized charge species [clofazimine (17) and the neutral uncoupler AU1235 (9)] had essentially no effects. Several uncouplers were inhibitors of isoprenoid biosynthesis enzymes, so we then used in silico screening to discover new inhibitors of TrkAd synthase that were also uncouplers. We found that vacuquinol (37) was one such compound, a result of interest because vacuquinol is a new drug lead for treating GBM and also has direct killing activity against *M. tuberculosis*. These observations led to the discovery of more potent analogs with activity against *M. tuberculosis* and *S. aureus* that also likely function, at least in part, as uncouplers. We also discovered that the new *S. aureus* growth inhibitor clomiphene, known to target cell wall biosynthesis by inhibiting UPPS, was an uncoupler, expected to lead to resistance-resistance. Overall, the results are of broad general interest because we find that many lipophilic, cationic species have activity against bacteria and that they act, at least in part, as uncouplers. In addition, many of the vacuquinol class of GBM cell growth inhibitors are also uncouplers, and some have promising activity against *M. tuberculosis* and *S. aureus*. The fact that the new *M. tuberculosis* drugs/drug leads bedaquiline and SQ109, as well compounds such as clofazimine (where there is renewed interest in treating *M. tuberculosis*), are protophosphate uncouplers that also have activity (or are activated by) enzyme targets makes it likely that this multitargeting will contribute to overall activity and resistance-resistance, making the further development of such multitarget leads of interest.

Methods

*M. smegmatis*, *S. cerevisiae*, *S. aureus*, and *M. tuberculosis* growth inhibition assays; the porcine liver mitochondria Δψ assay; Δψ and ΔΨ assays with IMV; MD simulation of Rv3378c; Rv3378c inhibition; DSC; and EPR were performed as described previously (13, 70, 71, 92), with full details given in *SI Methods*.

ACKNOWLEDGMENTS. We thank Prof. Tsutomu Hoshino for providing tuberculosis diphosphate and Prof. David B. Moody for his helpful comments. This work was supported by the US Public Health Service (NIH Grant GM065307), by a Harriet A. Harlin Professorship (to E.O.), and by the University of Illinois Foundation/Oldfield Research Fund. Work at the University of California San Diego is supported, in part, by the NIH, National Science Foundation, Howard Hughes Medical Institute, the National Biomedical Computation Resource (NBCR), and the San Diego Supercomputer Center (SDSC).
